DUBLIN--(BUSINESS WIRE)--The "Rhabdomyosarcoma Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" report has been added to ResearchAndMarkets.com's offering.
According to the research findings, most of the drug candidates for the treatment of RMS are being developed to be administered by the intravenous route. The main advantage associated with the intravenous route is that the drug can easily be entered into the bloodstream, or lymph vessels, resulting in high bioavailability of the drug in the body and quick onset of action of drug.
Several companies are developing combination therapies for the treatment of RMS, as these therapies are cost-effective and improve medication compliance by reducing burden of pills. For instance, (Dasatinib + Ganitumab) is a combination therapy under the Phase II stage of development by Bristol-Myers Squibb Company for the treatment of RMS. The drug candidate is a combination of small molecule (dasatinib) and monoclonal antibody (ganitumab), obtained from synthetic and natural source, respectively. It acts as Bcr-abl tyrosine kinase inhibitor and EphA2 receptor antagonist (dasatinib); and insulin-like growth factor-I receptor antagonist (ganitumab).
Combination therapies help to reduce frequency of dose administration, increase synergistic effect, and increase the potency of drugs for the treatment of RMS, thus driving the growth in pipeline.
Most of the companies are developing drug candidates using advanced technologies, and these drug candidates have showed positive efficacy in the clinical stage of development. For instance, Iproteos SL is developing its drug candidate using IPROTech technology platform which involves a combination of in-silico and in-vitro techniques. The technology encompasses state-of-the-art of various scientific fields, such as computational chemistry, modern organic synthesis, peptide chemistry, and experimental validation of potency, absorption, distribution, metabolism, and excretion (ADME) and permeability properties.
IPROTech platform is a versatile technology platform that can be applied to a wide variety of proteins. It is based on the repetition of cycles consisting of in-silico and in-vitro techniques. Some of the advantages of this technology include reduction of time and cost for manufacture of drugs, and the ability to render the drugs to reach intracellular targets.
Some of the key players involved in the development of RMS therapeutics include F. Hoffmann-La Roche Ltd., Epizyme Inc. and Novartis AG.
Key Topics Covered
1. Research Background
2. Research Methodology
3. Executive Summary
4. Pipeline Outlook
5. RMS Therapeutics Pipeline Analysis by Phase (2018)
6. Clinical Trials Review
7. Competitive Landscape
8. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/z5w3hx/global?w=4